Intermune has launched Esbriet (pirfenidone) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). PHARMACOLOGY Data suggest that pirfenidone has both antifibrotic and anti-inflammatory properties.1 Pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors.1 CLINICAL STUDIES The efficacy of pirfenidone in IPF was evaluated in the 72-week randomised double-blind CAPACITY studies (n=435 and n=344) and a further study conducted in Japan (n=219).2 The two international CAPACITY trials compared pirfenidone 2403mg/day with placebo. The Japanese trial used a lower dose of pirfenidone (1.8g/day) which was considered comparable with the dose used in the international studies on a weight-normalised basis.2,3 Efficacy data from CAPACITY trials The decline in per cent predicted forced vital capacity at week 72 was significantly lower with pirfenidone than placebo in one of the CAPACITY studies (p=0.001) but not the other (p=0.501); however, in the latter study, a significant benefit was observed at weeks 24, 36 and 48 (p=0.0001, p=0.011 and p=0.005, respectively). Fewer overall and IPF-related deaths occurred in the treatment arms than the placebo arms, although the studies were not powered to assess mortality.2 Similar results observed in Japan In the Japanese study, pirfenidone was associated with a significantly reduced mean decline in vital capacity at week 52 compared with placebo (p=0.042).1 Safety profile The most commonly reported adverse effects in the pirfenidone groups were nausea, diarrhoea, dyspepsia, fatigue, rash and photosensitivity reactions. To minimise the risk of rash and photosensitivity, patients should be advised to avoid exposure to direct sunlight (including UV lamps) and to apply sunscreen daily.1 ------------------------------------------------ Esbriet 267 mg hard capsules 1. Name of the medicinal product Esbriet® 267mg hard capsules 2. Qualitative and quantitative composition Each capsule contains 267 mg pirfenidone. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Hard capsule (capsule). Two piece capsules with a blue opaque body and gold opaque cap imprinted with “InterMune® 267 mg” in brown ink and containing a white to pale yellow powder. 4. Clinical particulars 4.1 Therapeutic indications Esbriet is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF). 4.2 Posology and method of administration Treatment with Esbriet should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of IPF. Posology Adults Upon initiating treatment, the dose should be titrated to the recommended daily dose of nine capsules per day over a 14-day period as follows: • Days 1 to 7: one capsule, three times a day (801 mg/day) • Days 8 to 14: two capsules, three times a day (1602 mg/day) • Day 15 onward: three capsules, three times a day (2403 mg/day) The recommended daily dose of Esbriet for patients with IPF is three 267 mg capsules three times a day with food for a total of 2403 mg/day. Doses above 2403 mg/day are not recommended for any patient. Patients who miss 14 consecutive days or more of Esbriet treatment should re-initiate therapy by undergoing the initial 2-week titration regimen up to the recommended daily dose. For treatment interruption of less than 14 consecutive days, the dose can be resumed at the previous recommended daily dose without titration. Dose adjustments and other considerations for safe use Gastrointestinal events: In patients who experience intolerance to therapy due to gastrointestinal side effects, patients should be reminded to take the medicinal product with food. If symptoms persist Esbriet may be reduced to 1-2 capsules (267 mg – 534 mg) 2-3 times/day with food with re-escalation to the recommended daily dose as tolerated. If symptoms continue, patients may be instructed to interrupt treatment for 1 to 2 weeks to allow symptoms to resolve. Photosensitivity reaction or rash: Patients who experience a mild to moderate photosensitivity reaction or rash should be reminded of the instruction to use a sunblock daily and to avoid sun exposure (see section 4.4). The dose of Esbriet may be reduced to 3 capsules/day (1 capsule three times a day). If the rash persists after 7 days, Esbriet should be discontinued for 15 days, with re-escalation to the recommended daily dose in the same manner as the dose escalation period. Patients who experience severe photosensitivity reaction or rash should be instructed to interrupt the dose and to seek medical advice (see section 4.4). Once the rash has resolved, Esbriet may be re-introduced and re-escalated up to the recommended daily dose at the discretion of the physician. Hepatic function: In the event of significant elevation of alanine and/or aspartate aminotransferases (ALT/AST) with or without bilirubin elevation, the dose of Esbriet should be adjusted or treatment discontinued according to the guidelines listed in section 4.4. Special populations Older people No dose adjustment is necessary in patients 65 years and older (see section 5.2). Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment (i.e. Child-Pugh Class A and B). However, since plasma levels of pirfenidone may be increased in some individuals with mild to moderate hepatic impairment, caution should be used with Esbriet treatment in this population. Patients should be monitored closely for signs of toxicity especially if they are concomitantly taking a known CYP1A2 inhibitor (see sections 4.5 and 5.2). Esbriet has not been studied in patients with severe hepatic impairment or end stage liver disease, and it should not be used in patients with these conditions (see sections 4.3, 4.4 and 5.2). It is recommended to monitor liver function during treatment, and dose adjustments may be necessary in the event of elevations (see sections 4.4 and 5.2). Renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. Esbriet therapy should not be used in patients with severe renal impairment (CrCl <30 ml/min) or end stage renal disease requiring dialysis (see sections 4.3 and 5.2). Paediatric population There is no relevant use of Esbriet in the paediatric population in the treatment of IPF. Method of administration Esbriet is to be swallowed whole with water and taken with food to reduce the possibility of nausea and dizziness (see sections 4.8 and 5.2). 4.3 Contraindications • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, • history of angioedema with pirfenidone (see section 4.4), • concomitant use of fluvoxamine (see section 4.5), • severe hepatic impairment or end stage liver disease (see sections 4.2 and 4.4), • severe renal impairment (CrCl <30 ml/min) or end stage renal disease requiring dialysis (see sections 4.2 and 4.4). 4.4 Special warnings and precautions for use Hepatic function Elevations in ALT and AST >3 × upper limit of normal (ULN) have been reported in patients receiving therapy with Esbriet. Rarely these have been associated with concomitant elevations in total serum bilirubin. Liver function tests (ALT, AST and bilirubin) should be conducted prior to the initiation of treatment with Esbriet, and subsequently at monthly intervals for the first 6 months and then every 3 months thereafter (see section 4.8). In the event of significant elevation of liver aminotransferases the dose of Esbriet should be adjusted or treatment discontinued according to the guidelines listed below. For patients with confirmed elevations in ALT, AST or bilirubin during treatment, the following dose adjustments may be necessary. Recommendations in case of ALT/AST elevations If a patient exhibits an aminotransferase elevation to >3 to ≤5 x ULN after starting Esbriet therapy, confounding medicinal products should be discontinued, other causes excluded, and the patient monitored closely. If clinically appropriate the dose of Esbriet should be reduced or interrupted. Once liver function tests are within normal limits Esbriet may be re-escalated to the recommended daily dose if tolerated. If a patient exhibits an aminotransferase elevation to ≤5 x ULN accompanied by symptoms or hyperbilirubinaemia, Esbriet should be discontinued and the patient should not be rechallenged. If a patient exhibits an aminotransferase elevation to >5 x ULN, Esbriet should be discontinued and the patient should not be rechallenged. Hepatic impairment In subjects with moderate hepatic impairment (i.e. Child-Pugh Class B), Esbriet exposure was increased by 60%. Esbriet should be used with caution in patients with pre-existing mild to moderate hepatic impairment (i.e. Child-Pugh Class A and B) given the potential for increased Esbriet exposure. Patients should be monitored closely for signs of toxicity especially if they are concomitantly taking a known CYP1A2 inhibitor (see sections 4.5 and 5.2). Esbriet has not been studied in individuals with severe hepatic impairment and Esbriet should not be used in patients with severe hepatic impairment. Photosensitivity reaction and rash Exposure to direct sunlight (including sunlamps) should be avoided or minimised during treatment with Esbriet. Patients should be instructed to use a sunblock daily, to wear clothing that protects against sun exposure, and to avoid other medicinal products known to cause photosensitivity. Patients should be instructed to report symptoms of photosensitivity reaction or rash to their physician. Severe photosensitivity reactions are uncommon. Dose adjustments or temporary treatment discontinuation may be necessary in mild to severe cases of photosensitivity reaction or rash (see section 4.2). Angioedema Reports of angioedema (some serious) such as swelling of the face, lips and/or tongue which may be associated with difficulty breathing or wheezing have been received in association with use of Esbriet in the post-marketing setting. Therefore, patients who develop signs or symptoms of angioedema following administration of Esbriet should immediately discontinue treatment. Patients with angioedema should be managed according to standard of care. Esbriet should not be used in patients with a history of angioedema due to Esbriet (see section 4.3). Dizziness Dizziness has been reported in patients taking Esbriet. Therefore, patients should know how they react to this medicinal product before they engage in activities requiring mental alertness or coordination (see section 4.7). In clinical studies, most patients who experienced dizziness had a single event, and most events resolved, with a median duration of 22 days. If dizziness does not improve or if it worsens in severity, dose adjustment or even discontinuation of Esbriet may be warranted. Fatigue Fatigue has been reported in patients taking Esbriet. Therefore, patients should know how they react to this medicinal product before they engage in activities requiring mental alertness or coordination (see section 4.7). Weight loss Weight loss has been reported in patients treated with Esbriet (see section 4.8). Physicians should monitor patients' weight, and when appropriate encourage increased caloric intake if weight loss is considered to be of clinical significance. 4.5 Interaction with other medicinal products and other forms of interaction Approximately 70–80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1. Consumption of grapefruit juice is associated with inhibition of CYP1A2 and should be avoided during treatment with pirfenidone. Fluvoxamine and inhibitors of CYP1A2 In a Phase 1 study, the co-administration of Esbriet and fluvoxamine (a strong inhibitor of CYP1A2 with inhibitory effects on other CYP isoenzymes [CYP2C9, 2C19, and 2D6]) resulted in a 4-fold increase in exposure to pirfenidone in non-smokers. Esbriet is contraindicated in patients with concomitant use of fluvoxamine (see section 4.3). Fluvoxamine should be discontinued prior to the initiation of Esbriet therapy and avoided during Esbriet therapy due to the reduced clearance of pirfenidone. Other therapies that are inhibitors of both CYP1A2 and one or more other CYP isoenzymes involved in the metabolism of pirfenidone (e.g. CYP2C9, 2C19, and 2D6) should be avoided during pirfenidone treatment. In vitro in vivo extrapolations indicate that strong and selective inhibitors of CYP1A2 (e.g. enoxacin) have the potential to increase the exposure to pirfenidone by approximately 2 to 4-fold. If concomitant use of Esbriet with a strong and selective inhibitor of CYP1A2 cannot be avoided, the dose of Esbriet should be reduced to 801 mg daily (one capsule, three times a day). Patients should be closely monitored for emergence of adverse reactions associated with Esbriet therapy. Discontinue Esbriet if necessary (see sections 4.2 and 4.4). Co-administration of Esbriet and 750 mg of ciprofloxacin (a moderate inhibitor of CYP1A2) increased the exposure to pirfenidone by 81%. If ciprofloxacin at the dose of 750 mg twice daily cannot be avoided, the dose of Esbriet should be reduced to 1602 mg daily (two capsules, three times a day). Esbriet should be used with caution when ciprofloxacin is used at a dose of 250 mg or 500 mg once or twice daily. Esbriet should be used with caution in patients treated with other moderate inhibitors of CYP1A2 (e.g. amiodarone, propafenone). Special care should also be exercised if CYP1A2 inhibitors are being used concomitantly with potent inhibitors of one or more other CYP isoenzymes involved in the metabolism of pirfenidone such as CYP2C9 (e.g. amiodarone, fluconazole), 2C19 (e.g. chloramphenicol) and 2D6 (e.g. fluoxetine, paroxetine). Cigarette smoking and inducers of CYP1A2 A Phase 1 interaction study evaluated the effect of cigarette smoking (CYP1A2 inducer) on the pharmacokinetics of Esbriet. The exposure to pirfenidone in smokers was 50% of that observed in non-smokers. Smoking has the potential to induce hepatic enzyme production and thus increase medicinal product clearance and decrease exposure. Concomitant use of strong inducers of CYP1A2 including smoking should be avoided during Esbriet therapy based on the observed relationship between cigarette smoking and its potential to induce CYP1A2. Patients should be encouraged to discontinue use of strong inducers of CYP1A2 and to stop smoking before and during treatment with pirfenidone. In the case of moderate inducers of CYP1A2 (e.g. omeprazole), concomitant use may theoretically result in a lowering of pirfenidone plasma levels. Co-administration of medicinal products that act as potent inducers of both CYP1A2 and the other CYP isoenzymes involved in the metabolism of pirfenidone (e.g. rifampicin) may result in significant lowering of pirfenidone plasma levels. These medicinal products should be avoided whenever possible. 4.6 Fertility, pregnancy and lactation Pregnancy There are no data from the use of Esbriet in pregnant women. In animals placental transfer of pirfenidone and/or its metabolites occurs with the potential for accumulation of pirfenidone and/or its metabolites in amniotic fluid. At high doses (≥1000 mg/kg/day) rats exhibited prolongation of gestation and reduction in fetal viability. As a precautionary measure, it is preferable to avoid the use of Esbriet during pregnancy. Breast-feeding It is unknown whether pirfenidone or its metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of pirfenidone and/or its metabolites in milk with the potential for accumulation of pirfenidone and/or its metabolites in milk (see section 5.3). A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue from Esbriet therapy, taking into account the benefit of breast-feeding for the child and the benefit of Esbriet therapy for the mother. Fertility No adverse effects on fertility were observed in preclinical studies (see section 5.3). 4.7 Effects on ability to drive and use machines No studies on the effects of the ability to drive and use machines have been performed. Esbriet may cause dizziness and fatigue, which could influence the ability to drive or use machines. 4.8 Undesirable effects The safety of Esbriet has been evaluated in clinical studies including 1345 healthy volunteers and patients. The most commonly reported (≥10%) adverse reactions during clinical study experience with Esbriet at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). Serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of Esbriet and placebo in clinical studies. Table 1 shows the adverse reactions reported at a frequency of ≥2% in 345 patients receiving Esbriet at the recommended dose of 2403 mg/day in two pivotal Phase 3 studies. Adverse reactions from post-marketing experience are also listed in Table 1. Adverse reactions are listed by System Organ Class (SOC) and within each frequency grouping [Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000)] the adverse reactions are presented in order of decreasing seriousness.
Table 1 Adverse reactions by SOC and MedDRA frequency |
Infections and infestations |
Common: |
Upper respiratory tract infection; urinary tract infection |
Blood and lymphatic system disorders |
Rare: |
Agranulocytosis1 |
Immune system disorders |
Uncommon: |
Angioedema1 |
Metabolism and nutrition disorders |
Common: |
Weight decreased; anorexia; decreased appetite |
Psychiatric disorders |
Common: |
Insomnia |
Nervous system disorders |
Common: |
Dizziness; headache; somnolence; dysgeusia |
Vascular disorders |
Common: |
Hot flush |
Respiratory, thoracic and mediastinal disorders |
Common: |
Dyspnoea; cough; productive cough |
Gastrointestinal disorders |
Very Common: |
Dyspepsia; nausea; diarrhoea |
Common: |
Gastroesophageal reflux disease; vomiting; abdominal distension; abdominal discomfort; abdominal pain; abdominal pain upper; stomach discomfort; gastritis; constipation; flatulence |
Hepatobiliary disorders |
Common: |
ALT increased; AST increased; gamma glutamyl transferase increased |
Rare: |
Total serum bilirubin increased in combination with increases of ALT and AST1 |
Skin and subcutaneous tissue disorders |
Very Common: |
Photosensitivity reaction; rash |
Common: |
Pruritus; erythema; dry skin; rash erythematous; rash macular; rash pruritic |
Musculoskeletal and connective tissue disorders |
Common: |
Myalgia; arthralgia |
General disorders and administration site conditions |
Very Common: |
Fatigue |
Common: |
Asthenia; non-cardiac chest pain |
Injury poisoning and procedural complications |
Common: |
Sunburn | 1. Identified through post-marketing surveillance Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via: United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard Ireland HPRA Pharmacovigilance Earlsfort Terrace IRL - Dublin 2 Tel: +353 1 6764971 Fax: +353 1 6762517 Website: www.hpra.ie e-mail: medsafety@hpra.ie Malta ADR Reporting The Medicines Authority Post-Licensing Directorate 203 Level 3, Rue D'Argens GŻR-1368 Gżira Website: www.medicinesauthority.gov.mt e-mail: postlicensing.medicinesauthority@gov.mt 4.9 Overdose There is limited clinical experience with overdose. Multiple doses of pirfenidone up to a dose of 4806 mg/day were administered as six 267 mg capsules three times daily to healthy adult volunteers over a 12-day dose escalation period. Adverse reactions were mild, transient, and consistent with the most frequently reported adverse reactions for pirfenidone. In the event of a suspected overdose, supportive medical care should be provided including monitoring of vital signs and close observation of the clinical status of the patient. 5. Pharmacological properties 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Immunosuppressants, other immunosuppressants, ATC code: L04AX05 The mechanism of action of pirfenidone has not been fully established. However, existing data suggest that pirfenidone exerts both antifibrotic and anti-inflammatory properties in a variety of in vitro systems and animal models of pulmonary fibrosis (bleomycin- and transplant-induced fibrosis). IPF is a chronic fibrotic and inflammatory pulmonary disease affected by the synthesis and release of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-α) and interleukin-1-beta (IL-1β) and pirfenidone has been shown to reduce the accumulation of inflammatory cells in response to various stimuli. Pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors such as, transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF). Clinical efficacy The clinical efficacy of Esbriet has been studied in three Phase 3, multicentre, randomised, double-blind, placebo-controlled studies in patients with IPF. Two of the Phase 3 studies (PIPF-004 and PIPF-006) were multinational, and the third (SP3) was conducted in Japan. PIPF-004 and PIPF-006 compared treatment with Esbriet 2403 mg/day to placebo. The studies were nearly identical in design, with few exceptions including an intermediate dose group (1197 mg/day) in PIPF-004. In both studies, treatment was administered three times daily for a minimum of 72 weeks. The primary endpoint in both studies was the change from Baseline to Week 72 in percent predicted Forced Vital Capacity (FVC). In study PIPF-004, the decline of percent predicted FVC from Baseline at Week 72 of treatment was significantly reduced in patients receiving Esbriet (N=174) compared with patients receiving placebo (N=174; p=0.001, rank ANCOVA). Treatment with Esbriet also significantly reduced the decline of percent predicted FVC from Baseline at Weeks 24 (p=0.014), 36 (p<0.001), 48 (p<0.001), and 60 (p<0.001). At Week 72, a decline from baseline in percent predicted FVC of ≥10% (a threshold indicative of the risk of mortality in IPF) was seen in 20% of patients receiving Esbriet compared to 35% receiving placebo (Table 2).
Table 2 Categorical assessment of change from Baseline to Week 72 in percent predicted FVC in study PIPF-004 |
|
Pirfenidone
2403 mg/day
(N = 174) |
Placebo
(N = 174) |
Decline of ≥10% or death or lung transplant |
35 (20%) |
60 (35%) |
Decline of less than 10% |
97 (56%) |
90 (52%) |
No decline (FVC change ≥0%) |
42 (24%) |
24 (14%) | Although there was no difference between patients receiving Esbriet compared to placebo in change from Baseline to Week 72 of distance walked during a six minute walk test (6MWT) by the prespecified rank ANCOVA, in an ad hoc analysis, 37% of patients receiving Esbriet showed a decline of ≥50 m in 6MWT distance, compared to 47% of patients receiving placebo. In study PIPF-006, treatment with Esbriet (N=171) did not reduce the decline of percent predicted FVC from Baseline at Week 72 compared with placebo (N=173; p=0.501). However, treatment with Esbriet reduced the decline of percent predicted FVC from Baseline at Weeks 24 (p<0.001), 36 (p=0.011), and 48 (p=0.005). At Week 72, a decline in FVC of ≥10% was seen in 23% of patients receiving Esbriet and 27% receiving placebo (Table 3).
Table 3 Categorical assessment of change from Baseline to Week 72 in percent predicted FVC in study PIPF-006 |
|
Pirfenidone
2403 mg/day
(N = 171) |
Placebo
(N = 173) |
Decline of ≥10% or death or lung transplant |
39 (23%) |
46 (27%) |
Decline of less than 10% |
88 (52%) |
89 (51%) |
No decline (FVC change ≥ 0%) |
44 (26%) |
38 (22%) | The decline in 6MWT distance from Baseline to Week 72 was significantly reduced compared with placebo in this study (p <0.001, rank ANCOVA). Additionally, in an ad hoc analysis, 33% of patients receiving Esbriet showed a decline of ≥50 m in 6MWT distance, compared to 47% of patients receiving placebo. In a pooled analysis of survival in PIPF-004 and PIPF-006 the mortality rate with Esbriet 2403 mg/day group was 7.8% compared with 9.8% with placebo (HR 0.77 [95% CI, 0.47–1.28]). The third study (SP3) in Japanese patients compared pirfenidone 1800 mg/day (comparable to 2403 mg/day in the US and European populations of PIPF-004/006 on a weight-normalised basis) with placebo (N=110, N=109, respectively). Treatment with pirfenidone significantly reduced mean decline in vital capacity (VC) at Week 52 (the primary endpoint) compared with placebo (-0.09±0.02 l versus -0.16±0.02 l respectively, p=0.042). Paediatric population The European Medicines Agency has waived the obligation to submit the results of studies with Esbriet in all subsets of the paediatric population in IPF (see section 4.2 for information on paediatric use). 5.2 Pharmacokinetic properties Absorption Administration of Esbriet with food results in a large reduction in Cmax (by 50%) and a smaller effect on AUC, compared to the fasted state. Following oral administration of a single dose of 801 mg to healthy older adult volunteers (50-66 years of age) in the fed state, the rate of pirfenidone absorption slowed, while the AUC in the fed state was approximately 80-85% of the AUC observed in the fasted state. A reduced incidence of adverse events (nausea and dizziness) was observed in fed subjects when compared to the fasted group. Therefore, it is recommended that Esbriet be administered with food to reduce the incidence of nausea and dizziness. The bioavailability of pirfenidone has not been determined in humans. Distribution Pirfenidone binds to human plasma proteins, primarily to serum albumin. The overall mean binding ranged from 50% to 58% at concentrations observed in clinical studies (1 to 100 μg/ml). Mean apparent oral steady-state volume of distribution is approximately 70 l, indicating that pirfenidone distribution to tissues is modest. Biotransformation Approximately 70–80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1. In vitro and in vivo studies to date have not detected any activity of the major metabolite (5-carboxy-pirfenidone), even at concentrations or doses greatly above those associated with activity of pirfenidone itself. Elimination The oral clearance of pirfenidone appears modestly saturable. In a multiple-dose, dose-ranging study in healthy older adults administered doses ranging from 267 mg to 1335 mg three times a day, the mean clearance decreased by approximately 25% above a dose of 801 mg three times a day. Following single dose administration of pirfenidone in healthy older adults, the mean apparent terminal elimination half-life was approximately 2.4 hours. Approximately 80% of an orally administered dose of pirfenidone is cleared in the urine within 24 hours of dosing. The majority of pirfenidone is excreted as the 5-carboxy-pirfenidone metabolite (>95% of that recovered), with less than 1% of pirfenidone excreted unchanged in urine. Special populations Hepatic impairment The pharmacokinetics of pirfenidone and the 5-carboxy-pirfenidone metabolite were compared in subjects with moderate hepatic impairment (Child-Pugh Class B) and in subjects with normal hepatic function. Results showed that there was a mean increase of 60% in pirfenidone exposure after a single dose of 801 mg pirfenidone (3 x 267 mg capsule) in patients with moderate hepatic impairment. Pirfenidone should be used with caution in patients with mild to moderate hepatic impairment and patients should be monitored closely for signs of toxicity especially if they are concomitantly taking a known CYP1A2 inhibitor (see sections 4.2 and 4.4). Esbriet is contraindicated in severe hepatic impairment and end stage liver disease (see sections 4.2 and 4.3). Renal impairment No clinically relevant differences in the pharmacokinetics of pirfenidone were observed in subjects with mild to severe renal impairment compared with subjects with normal renal function. The parent drug is predominantly metabolised to 5-carboxy-pirfenidone, and the pharmacokinetics of this metabolite is altered in subjects with moderate to severe renal impairment. However, the predicted amount of metabolite accumulation at steady state is not pharmacodynamically important because the terminal elimination half-life is only 1–2 hours in these subjects. No dose adjustment is required in patients with mild to moderate renal impairment who are receiving pirfenidone. The use of pirfenidone is contraindicated in patients with severe renal impairment (CrCl <30ml/min) or end stage renal disease requiring dialysis (see sections 4.2 and 4.3). Population pharmacokinetic analyses from 4 studies in healthy subjects or subjects with renal impairment and one study in patients with IPF showed no clinically relevant effect of age, gender or body size on the pharmacokinetics of pirfenidone. 5.3 Preclinical safety data Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. In repeated dose toxicity studies increases in liver weight were observed in mice, rats and dogs; this was often accompanied by hepatic centrilobular hypertrophy. Reversibility was observed after cessation of treatment. An increased incidence of liver tumours was observed in carcinogenicity studies conducted in rats and mice. These hepatic findings are consistent with an induction of hepatic microsomal enzymes, an effect which has not been observed in patients receiving Esbriet. These findings are not considered relevant to humans. A statistically significant increase in uterine tumours was observed in female rats administered 1500 mg/kg/day, 37 times the human dose of 2403 mg/day. The results of mechanistic studies indicate that the occurrence of uterine tumours is probably related to a chronic dopamine-mediated sex hormone imbalance involving a species specific endocrine mechanism in the rat which is not present in humans. Reproductive toxicology studies demonstrated no adverse effects on male and female fertility or postnatal development of offspring in rats and there was no evidence of teratogenicity in rats (1000 mg/kg/day) or rabbits (300 mg/kg/day). In animals placental transfer of pirfenidone and/or its metabolites occurs with the potential for accumulation of pirfenidone and/or its metabolites in amniotic fluid. At high doses (≥450 mg/kg/day) rats exhibited a prolongation of oestrous cycle and a high incidence of irregular cycles. At high doses (≥1000 mg/kg/day) rats exhibited a prolongation of gestation and reduction in fetal viability. Studies in lactating rats indicate that pirfenidone and/or its metabolites are excreted in milk with the potential for accumulation of pirfenidone and/or its metabolites in milk. Pirfenidone showed no indication of mutagenic or genotoxic activity in a standard battery of tests and when tested under UV exposure was not mutagenic. When tested under UV exposure pirfenidone was positive in a photoclastogenic assay in Chinese hamster lung cells. Phototoxicity and irritation were noted in guinea pigs after oral administration of pirfenidone and with exposure to UVA/UVB light. The severity of phototoxic lesions was minimised by application of sunscreen. Environmental Risk Assessment (ERA) Pirfenidone is not considered to present a potential risk to surface water, microorganisms and ground water or to sediment-dwelling invertebrates. 6. Pharmaceutical particulars 6.1 List of excipients Capsule content Microcrystalline cellulose Croscarmellose sodium Povidone Magnesium stearate Capsule shell: body Indigo carmine (E132) Titanium dioxide (E171) Gelatin Capsule shell: cap Red iron oxide (E172) Yellow iron oxide (E172) Titanium dioxide (E171) Gelatin Imprinting Inks Brown S-1-16530 or 03A2 inks containing: Shellac Iron oxide black (E172) Iron oxide red (E172) Iron oxide yellow (E172) Propylene glycol Ammonium hydroxide 6.2 Incompatibilities Not applicable. 6.3 Shelf life 4 years for blisters. 3 years for bottles. 6.4 Special precautions for storage Do not store above 30°C. 6.5 Nature and contents of container Pack sizes 2-week treatment initiation pack 1 x PVC/PE/PCTFE aluminium foil blister card containing 21 capsules, packaged together with 1 x PVC/PE/PCTFE aluminium foil blister card containing 42 capsules, for a total of 63 capsules per pack. 1-week treatment maintenance pack 1 x PVC/PE/PCTFE aluminium foil blister card containing 63 capsules. 4-week treatment maintenance pack 4 x 1-week treatment packs of PVC/PE/PCTFE aluminium foil blister cards each containing 63 capsules for a total of 252 capsules per pack. 250 ml white HDPE bottle with child-resistant closure containing 270 capsules. Not all pack sizes may be marketed. 6.6 Special precautions for disposal and other handling No special requirements. 7. Marketing authorisation holder InterMune UK Ltd. Grove House 2nd Floor 248A Marylebone Road London NW1 6JZ United Kingdom Tel.: +44 (0) 203 514 0675 Fax.: +44 (0) 3308 080969 8. Marketing authorisation number(s) EU/1/11/667/001 EU/1/11/667/002 EU/1/11/667/003 EU/1/11/667/004 9. Date of first authorisation/renewal of the authorisation Date of first authorisation: 28 February 2011 10. Date of revision of the text 06/2014 Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. POM 20140627-PFD-GbrIrlMlt-EN.00
欧洲上市及制造商 InterMune公司(英国)有限公司 美国FDA批准Esbriet(pirfenidone)治疗特发性肺纤维化 2014年10月15日美国食品和药品监督管理局(FDA)批准Esbriet (吡非尼酮[pirfenidone])为特发性肺纤维化的治疗(IPF)。 特发性肺纤维化是一种条件其中随时间肺逐渐地成为瘢痕。其结果,有IPF患者经受气短,咳嗽,和很难参加每天体力活动。对IPF的当前治疗包括氧疗,肺功能康复,和肺移植。 FDA药品评价和研究中心药物评价II室主任Curtis J. Rosebraugh,M.D.,M.P.H. 说:“对有特发性肺纤维化患者,一种严重 ,慢性肺病,Esbriet提供一种新的治疗选择” 。“我们将通过批准影响治疗公共卫生条件的产品继续帮助推动先进药物治疗。” FDA授予Esbriet 快速通道,优先审评,孤儿产品,和突破性治疗指定。Esbriet正在超出监管局完成药物申请审评产品处方药物使用者费用被批准目标日期11月23日。 Esbriet作用于涉及肺组织瘢痕化的多个途径。在1,247例IPF患者三项临床试验确定安全性和有效性。在用力肺活量下降– 在可能的最深呼吸后从肺可以强制呼出的空气量 –接受 Esbriet患者与接受安慰剂患者比较显著减少。 有严重肝脏问题,肾病终末期,或需要透析患者建议不用Esbriets。应与食物服用Esbriet以减小恶心和眩晕的潜能。患者应避免或暴露至阳光和太阳灯最小和涂抹防晒霜和穿防护服,因为 Esbriet可能致患者更容易晒伤。 Esbriet最常见副作用是恶心,皮疹,腹痛,上呼吸道感染,腹泻,疲乏,头痛,消化不良,眩晕,呕吐,食欲减退/厌食,胃-食道回流病,鼻窦炎,失眠,体重减轻,和关节炎。 FDA在今天还批准Ofev (nintedanib)为治疗特发性肺纤维化[ IPF]。 Esbriet由加州布里斯班InterMune公司制造。 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418991.htm ------------------------------------------------ 产地国家: 英国 原产地英文商品名: Esbriet 267mg hard capsules 252Caps 原产地英文药品名: pirfenidone 中文参考商品译名: Esbriet硬胶囊 267毫克/硬胶囊 252硬胶囊/小盒(63x4小盒) 中文参考药品译名: 吡菲尼酮 生产厂家英文名: InterMune
|